Number: 201201124 Principal Investigator: Wang-Gillam, Andrea
Title: Phase IB Study of FOLFIRINOX and PF-04136309 in Patients with Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Phase: I Disease Site: Pancreas
Participating Site(s):
Main Campus
Map and Directions
South County
Map and Directions
West County
Map and Directions
Contact: 800-600-3606 or

The purpose of this research study is to find the best dose of the study drug (PF-04136309) in combination with FOLFIRINOX as well as to see what the side effects of this treatment regimen are. PF-04136309 is considered investigational, which means that it has not been approved by the U.S. Food and Drug Administration (FDA). FOLFIRINOX is a combination of several drugs that are given
together the same way every time: 5FU, leucovorin, irinotecan, and oxaliplatin. This combination of drugs is supported by the National Comprehensive Cancer Network for use in patients with pancreas cancer that cannot be removed surgically. It has not, however, been approved by the FDA.
More Information: #
Internal Protocol Documents (requires Siteman administrative database password)